e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Is it time to move away from short-acting beta-agonists in asthma management?
Matthew J. Martin, Tim W. Harrison
Source:
Eur Respir J, 53 (4) 1802223; 10.1183/13993003.02223-2018
Journal Issue:
April
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Matthew J. Martin, Tim W. Harrison. Is it time to move away from short-acting beta-agonists in asthma management?. Eur Respir J, 53 (4) 1802223; 10.1183/13993003.02223-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Concomitant use of long-acting beta-agonists with inhaled corticosteroids among asthma patients in the UK primary care
Source: Annual Congress 2007 - Miscellaneous epidemiological aspects of respiratory disease
Year: 2007
Long-acting bronchodilators in COPD: where are we now and where are we going?
Source: Breathe 2014; 10:110-120
Year: 2014
Is beta-agonist alone prescribed in case of uncontrolled asthma?
Source: Annual Congress 2008 - Asthma: growing understanding of influential factors
Year: 2008
Switching to maintenance and reliever inhaled corticosteroid/long acting beta agonist: a real-world pilot evaluation in a regional paediatric difficult asthma clinic.
Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world
Year: 2020
Is there a problem with inhaled corticosteroid use in COPD?
Source: Virtual Congress 2020 – Airway diseases
Year: 2020
Inhaled beta2-agonists in asthma management: an evolving story
Source: Breathe 2016; 12: 375-377
Year: 2016
The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014
Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD
Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases
Year: 2019
Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence?
Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents?
Year: 2020
Identification of asthma level of control using administrative data of short-acting beta-agonist inhalers purchase
Source: International Congress 2016 – Monitoring airway diseases with clinical tools
Year: 2016
The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments
Source: International Congress 2015 – New insights into exercise and muscle performance
Year: 2015
What to use INSTEAD of inhaled corticosteroids in COPD?
Source: Eur Respir J 2014; 44: 1391-1393
Year: 2014
Cessation of long-acting beta2-agonist in children with persistent asthma on inhaled corticosteroids
Source: Eur Respir J 2016; 48: 558-560
Year: 2016
Overuse of short-acting beta-agonists (SABA) and risk factors among patients with asthma
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020
Regular use of inhaled corticosteroids and the long-term prevention of hospitalisation for asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 8s
Year: 2002
Can long-acting β2 agonists substitute inhaled corticosteroids in stable persistent asthma
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Bronchodilator therapies for severe asthma
Source: Eur Respir Mon 2011; 51: 253-267
Year: 2011
The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype
Source: International Congress 2015 – COPD and lung function: risk factors and outcomes
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept